Identification of a microbiome signature predicting immune checkpoint inhibitor outcomes across multiple cancer types in the MITRE study.
Authors: Philippa Gail Corrie, Sarah Joanne Welsh, Grant D. Stewart, Gary Doherty, Kevin Vervier, Anne Neville, Christine Parkinson, Kate Fife, Guy Faust, Kamalram Thippu Jayaprakash, Thomas R. Geldart, Ewan Brown, Matthew Wheater, Jenny Penelope Nobes, David Bruce, Nikos Demiris, Katy Marie Dalchau, David Adams, Mat Robinson, Trevor Lawley
Journal: Journal of Clinical Oncology (2021)

TPS2665 Background: The gut microbiome is implicated as a biomarker of response to immune checkpoint inhibitors (ICIs), based on preclinical mouse models and preliminary observations in limited patient series. Furthermore, early reports suggest faecal microbial transfer may have therapeutic potential, converting ICI non-responders to responders. So far, identification of specific responsible bacterial taxa has been inconsistent between published studies, which limits future application. By culturing and metagenomic sequencing of stool sample bacteria, our group has identified a unique microbiome signature, which appears to be predictive of response to ICIs across all key published series as well as our own melanoma patient series (Robinson M et al, J Immunother Cancer 2020;8(suppl 3):A404). Because the patient numbers in all published series remain low, we are now further exploring and validating this microbiome signature in a larger scale study across several different cancer types. Methods: MITRE (Microbiome Immunotherapy Toxicity and Response Evaluation) is a UK NIHR portfolio multi-centre prospective study funded jointly by Cancer Research UK and Microbiotica (NCT04107168). Up to 1800 patients receiving ICIs will be recruited over a 5-year period. In the first stage, 300 patients with advanced melanoma (cohort 1: anti-PD1 monotherapy, cohort 2: anti-PD1+anti-CTLA-4 combination), renal cancer (cohort 3: anti-PD(L)1+kinase inhibitor, cohort 4: anti-PD1+anti-CTLA-4 combination) and non-small cell lung cancer (cohort 5: anti-PD(L)1 monotherapy, cohort 6: anti-PD(L)1+chemotherapy+anti-angiogenic) are being recruited, 50 patients to each cohort. A cohort-specific, simulation-based power calculation will then be performed, guiding subsequent recruitment. Stool and blood are collected prior to treatment, at 3, 6 and 12 months, or disease progression (whichever is sooner), as well as after any grade &gt;3 immune-related adverse events. Patients collect and freeze their own stool samples which are cultured and subjected to shotgun metagenomic sequencing. Plasma, whole blood, buffy coat, RNA and PBMCs are being stored, for correlative studies. Any tumour, or organ biopsies, taken prior to and during treatment are also being collected. Clinical data collection includes treatment, disease response (using RECIST criteria) and toxicity. The primary outcome measure is 1 year progression-free survival. Patients are also asked to invite a household member to be part of the study control group. Recruitment started in July 2020. The Covid-19 pandemic hindered recruitment last year, but the protocol was amended to incorporate a Covid-19 substudy (to document testing, infection and vaccination) and adapt processes for remote trial delivery as much as possible. As of February 2021, 7 sites have opened, 17 patients and 5 household controls have been recruited. Clinical trial information: NCT04107168.